Judicialization of Zolgensma in the Ministry of Health: costs and clinical profile of patients
ABSTRACT OBJECTIVE To investigate the costs and profile of patients who have filed a lawsuit against the Ministry of Health for the treatment of spinal muscular atrophy (SMA) with the onasemnogene abeparvovec (Zolgensma®). METHODS This is a cross-sectional, descriptive study with a census design, ba...
Saved in:
Main Authors: | Ana Katheryne Miranda Kretzschmar (Author), Ellen Teixeira (Author), Dayani Galato (Author), Everton Nunes da Silva (Author) |
---|---|
Format: | Book |
Published: |
Universidade de São Paulo,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pricing Zolgensma - the world's most expensive drug
by: Mark Nuijten
Published: (2022) -
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
by: Rebecca Dean, et al.
Published: (2021) -
ID236 Zolgensma no tratamento da Atrofia Muscular Espinhal: Acordos de Acesso Gerenciado no mundo
by: Laís Lessa Neiva Pantuzza, et al.
Published: (2024) -
Eficácia, segurança e aspectos regulatórios dos medicamentos órfãos para doenças raras: o caso Zolgensma®
by: Rachel Riera, et al.
Published: (2019) -
International Judicial Legitimacy New Voices and Approaches
by: Chaib, André Nunes
Published: (2020)